Mark J. Gergen - 01 Mar 2023 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role: President and CEO, Director
Signature: /s/ Harry J. Leonhardt, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 02 Mar 2023, 17:17:46 UTC
Previous filing: 03 Feb 2023
Next filing: 04 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	Common Stock	Award	$0	+269,586	+81%	$0.000000	601,610	01 Mar 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PSTX	Employee Stock Option (Right to Buy)	Award	$0	+364,060		$0.000000	364,060	01 Mar 2023	Common Stock	364,060	$5.35	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments.
F2	Includes 1,710 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on September 20, 2021.
F3	12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.